To test the clinical relevance of these QCS features, we retrospectively analyzed data from a phase 1 clinical trial of T-DXd (NCT02564900; DS8201-A-J101 [J101])10 comprising data from 186 patients with previously treated HER2-positive and HER2-negative BC. This evidence concerns the gene ERBB2 and breast cancer.